The weight-loss biotech Viking Therapeutics (NASDAQ: VKTX) saw its stock get absolutely slammed on Dec. 18, falling 18% as a ...

Stocks on the Move: Uber, Carmax, Novo Nordisk, Eli Lilly, Merck, Crown Castle and Accenture Justice Kyra Harris Bolden ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Merck's experimental two-drug combination met the main goal of significantly suppressing replication of the HIV-1 virus in ...

U.S. drugmaker Merck on Wednesday signed a deal worth up to $2 billion with Hansoh Pharmaceuticals to develop and ...

News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen ...

Merck announced a weight loss drug deal Wednesday with China-based Hansoh worth up to $2 billion for the pill code-named ...

Merck (MRK) stock in focus as company reports mixed results in Phase 3 trials for HIV therapy islatravir in combination with ...

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024. See why I rate ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion.

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

The low-risk approach by the drug giant is a sign of the extent of Eli Lilly and Novo Nordisk’s dominance in the weight-loss ...